Transcatheter Mitral Valve Replacement Attracts Interest From Edwards, Others
This article was originally published in The Gray Sheet
Leading the development of transcatheter mitral valve replacement therapies is one of Edwards Lifesciences’ strategic imperatives, the company explained during its recent investor conference. The potential market is large, but so are the technical hurdles. Medtronic and other smaller players are also taking steps.
You may also be interested in...
Neovasc Inc. is targeting two highly underserved markets in cardiology – refractory angina and mitral valve disease – with unique transcatheter solutions. The angina device, called the Neovasc Reducer, is expected to enter the European market early next year.
The agency’s Circulatory System Devices Panel narrowly voted in favor of Abbott’s MitraClip transcatheter mitral valve repair system to reduce mitral regurgitation. But the discussions about the clinical evidence on the technology were complex and the panel’s support for Abbott’s PMA was not unanimous.
In this week's podcast edition of Five Must-Know Things: landmark results for lecanemab in Alzheimer’s; other Alzheimer’s players rise after the lecanemab results; Leqvio’s importance to Novartis; Pfizer’s secret sauce for digitalization; and Amgen’s clinical trial diversity efforts.